George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,913.00
Bid: 1,916.00
Ask: 1,918.00
Change: 59.00 (3.18%)
Spread: 2.00 (0.104%)
Open: 1,861.00
High: 1,920.00
Low: 1,861.00
Prev. Close: 1,854.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Brexit: No V-shaped chart for you!

Tue, 23rd Jun 2020 11:28

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

BREXIT: NO V-SHAPED CHART FOR YOU! (1016 GMT)

It's been four years since the British people voted to leave the European Union and it's
pretty fair to say that there's yet limited visibility on how Brexit will actually work out.
Deal? No Deal? Who knows?

One thing for sure though, is that while both the EU and the British government are still
locked into "interminably tedious" (to quote UBS' Paul Donovan) divorce talks, getting out of
the bloc has done little for UK stocks for now at least.

Looking for stocks performances in USD terms, British stocks are clear laggards in
comparison to the world's biggest regions:

Specifically against the euro zone, it's also clear that the FTSE 100 and 250 have barely
recovered from the Brexit shock while the STOXX 600 and STOXX 50E are more comfortably above
where they were four years ago.

One very interesting note in today's Politico London Playbook is that "The history books
will show that three-and-a-half years of chaotic Brexit drama finally came to an end on January
31, 2020 (the actual date when the UK left the EU) the very day that the first case of
coronavirus was confirmed on these shores."

(Julien Ponthus and Thyagaraju Adinarayan)

*****

AT LAST, A V-SHAPED CHART! (0852 GMT)

The PMIs this morning sure gave the bulls a boost! Particularly the DAX and the CAC which
are up 2% and 1.4% respectively.

The data was much better than expected and it does help the V-shaped recovery narrative that
so many investors believe is currently priced in the markets.

Because shapes matter, the chart of the France's June PMI is worth a quick look:

Now, of course, while the PMIs from France, Germany, the euro zone and UK have been welcomed
with a burst of enthusiasm across the continent's stock markets, there's also some cold water
being poured on the data.

"Today’s PMIs for June are almost entirely worthless", Panmure Gordon chief economist Simon
French commented on Twitter.

"Not a criticism of the data providers - simply that in such unprecedented circumstances any
calibration across to output levels is impossible," he said, adding that "the data is good for
headlines and pretty charts - little else". Ouch..

Here's a bit of reading on the actual data:

French business activity unexpectedly rebounds into growth in June [nL8N2DZ4MD}

German private sector slowly digging its way out of recession

Euro zone downturn eased in June as economies opened up

Britain's coronavirus slump tapers off in June, PMIs show

(Julien Ponthus and Thyagaraju Adinarayan)

*****

OPENING SNAPSHOT: FRENCH, GERMAN UPBEAT JUNE PMIS BOOST STOXX (0735 GMT)

News that French business activity rebounded more than expected in June to above the 50
points mark boosted European stock markets 15 minutes after the open.

Paris' CAC 40 quickly doubled its gains to 1.2%, lifting other regional bourses with it.

At 0730 GMT, the German data also came in better than expected (yet below 50) and gave an
additional boost to the DAX which quickly made it to +1.8%.

Five minutes after the German data, the STOXX 600 was trading at 1.1%.

There were signs that traders were switching to risk on with cyclicals having a jolly good
time: autos and banks were up 2.5% and 2.4% respectively.

There were also no shortage of individual movers, notably:

A 17.6% rebound by shares in Wirecard. Hikma shares are down 8.5% as investor Boehringer
Ingelheim is about to sell its stake.

Alberts shares up 6% after a COVID-19 trading update.

(Julien Ponthus)

*****

ON THE RADAR: FRESH PMIS, UK LOCKDOWN EASING AND SANOFI'S VACCINE (0630 GMT)

Nothing like a bit of good news to start the day: French drugmaker Sanofi said it expects to
get approval by the first half of next year - faster than previously anticipated - for the
potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline.

While second-wave fears are spreading in Asia, Brasil and in some U.S. states notably,
Britain is get ready to ease the lockdown further with cinemas, museums and galleries in England
being expected to be allowed to reopen from July 4. A review of social distancing measures is
also eagerly awaited in the hospitality industry.

So all of that could give a boost to many FTSE 250 companies, particularly in the travel and
leisure segment.

Much of the optimism in the upcoming session will however depend on a fresh batch of PMIs
from the UK, France, Germany and the euro zone. Expectations are for a sizeable rebound.

There are plenty of challenges ahead to bring the economy back to normal, and that can be
seen with Volkswagen's Mexican unit which said about 2% of its workers tested for coronavirus
had contracted the disease at some point.

On the corporate front, a U.S. federal appeals court blocked California from requiring that
Bayer label its glyphosate-based weed killer Roundup with a cancer warning, handing
the company a victory in its ongoing litigation over the product.

Boehringer Ingelheim, a major shareholder in Hikma Pharmaceuticals, is exiting the
drugmaker by selling most of its nearly one billion pound stake to institutional investors.

Wirecard should provide some action still this morning, down about 5% in pre market trading
after the plunge of the stock in the last sessions.

Kloeckner shares up 13.4% in early trade after the company gives Q2 outlook.

Shares in Cosmo Pharmaceuticals are up 1.6% in premarket trade after the company
announced regulatory approval of Gi Genius in Israel.

Closing the Refinitiv deal won't be a walk in the park for LSE: European Union antitrust
regulators warned about the possible anti-competitive effects of $27 billion takeover and
launched a four-month investigation into the deal.

(Julien Ponthus and Stefano Rebaudo)

*****

MORNING CALL: THE PATH IS CLEAR FROM TRADE DRAMA (0536 GMT)

European investors are waking up to a "fully intact" U.S./China trade deal, having missed in
their sleep the wild swings which followed White House trade adviser Peter Navarro saying it was
over.

Trump later denied the deal collapsed, which triggered a rebound in Asian shares and cleared
the path for an upbeat open in Europe.

Futures for the STOXX50E and the DAX are currently both up 0.9% while it's about 0.4% for
the FTSE100.

While there's relief the two economic superpowers have not entered a full-on trade war,
COVID 19 second wave fears are pretty much intact with infections on the rise in Brasil and
many U.S. states for example.

In Europe, the publication of June PMIs this morning should shed a bit more light on the
shape of the recovery help set a trend for this session.

(Julien Ponthus)

*****

More News
22 Feb 2024 07:51

Hikma lifts dividend after double-digit growth in 2023

(Sharecast News) - Hikma Pharmaceuticals impressed the market with its annual results on Thursday as it bumped up its dividend by almost a third following double-digit growth in core revenues and profits in 2023.

Read more
15 Feb 2024 14:42

UK earnings, trading statements calendar - next 7 days

Friday 16 February 
NatWest Group PLCFull Year Results
Segro PLCFull Year Results
TBC Bank Group PLCFull Year Results
Monday 19 February 
Bank of Cyprus Holdings PLCFull Year Results
MoneySupermarket.com PLCFull Year Results
Transense Technologies PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 20 February 
Antofagasta PLCFull Year Results
Barclays PLCFull Year Results
BHP Group LtdHalf Year Results
Coca-Cola Europacific Partners PLCFull Year Results
Gran Tierra Energy IncFull Year Results
InterContinental Hotels Group PLCFull Year Results
Petra Diamonds LtdHalf Year Results
Springfield Properties PLCHalf Year Results
Wednesday 21 February 
BAE Systems PLCFull Year Results
Conduit Holdings LtdFull Year Results
Glencore PLCFull Year Results
HSBC Holdings PLCFull Year Results
Rio Tinto PLCFull Year Results
Riverstone Credit Opportunities Income PLCFull Year Results
Tate & Lyle PLCTrading Statement
Thursday 22 February 
Anglo American PLCFull Year Results
Genus PLCHalf Year Results
Hargreaves Lansdown PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Indivior PLCFull Year Results
Jupiter Fund Management PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
ME Group International PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
WPP PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
2 Feb 2024 07:23

Hikma agrees to settle US opioid claims

(Sharecast News) - Hikma Pharmaceuticals announced an agreement in principle to address the majority of opioid-related claims filed against it by various US states, local communities and tribal nations on Friday.

Read more
1 Feb 2024 20:00

EARNINGS AND TRADING: Tandem FY sales down 17%; Hikma's opioid deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2024 09:29

LONDON BROKER RATINGS: Berenberg cuts target prices for miners

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Wednesday:

Read more
20 Dec 2023 09:25

LONDON BROKER RATINGS: UBS cuts DS Smith; Kepler likes Genus

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
19 Dec 2023 09:11

LONDON BROKER RATINGS: Peel Hunt raises Flutter to 'buy' from 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
7 Nov 2023 13:08

Jefferies downgrades Hikma to 'hold'

(Sharecast News) - Jefferies downgraded Hikma Pharmaceuticals on Tuesday to 'hold' from 'buy' and cut the price target to 1,940p from 2,125p.

Read more
7 Nov 2023 09:28

LONDON BROKER RATINGS: Watches of Switzerland impresses HSBC; Asos cut

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
7 Nov 2023 07:43

LONDON BRIEFING: AB Foods hails Primark; Beazley premiums rise

(Alliance News) - London's FTSE 100 is called to open in the red on Tuesday, following Asian equities lower, as the good feeling in equity markets after the softer US jobs data on Friday gives way to some caution.

Read more
6 Nov 2023 12:01

Berenberg stays at 'hold' on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg reiterated their 'hold' rating and 2,100.0p target price on Hikma Pharmaceuticals on Monday, saying a "lighter" second half was playing out in its injectables unit.

Read more
3 Nov 2023 09:31

LONDON BROKER RATINGS: JPMorgan lifts Smith & Nephew

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
2 Nov 2023 15:12

London close: Stocks rise as BoE keeps rates steady

(Sharecast News) - London's stock markets ended the day on a positive note on Thursday, following the Bank of England's decision to maintain interest rates as markets widely expected.

Read more
2 Nov 2023 08:53

TOP NEWS: Hikma Pharmaceuticals upgrades Generics and Branded guidance

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday updated its full year guidance across its divisions after reporting continued "strong momentum" in a trading update.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.